Published in Biochem Pharmacol on February 01, 1977
Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci U S A (1994) 1.75
Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J Clin Invest (1982) 1.51
Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci U S A (1994) 1.50
Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. Proc Natl Acad Sci U S A (1981) 1.28
A 22-kd protein (sorcin/V19) encoded by an amplified gene in multidrug-resistant cells, is homologous to the calcium-binding light chain of calpain. EMBO J (1986) 1.05
The pH partition theory predicts the accumulation and toxicity of doxorubicin in normal and low-pH-adapted cells. Br J Cancer (1999) 0.86
A comparison of adriamycin and mAMSA in vitro: cell lethality and SCE studies. Br J Cancer (1981) 0.85
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells. Br J Cancer (1990) 0.81
Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line. Br J Cancer (1988) 0.78
A comparison of adriamycin and mAMSA. II. Studies with V79 and human tumour multicellular spheroids. Cancer Chemother Pharmacol (1987) 0.78
A short-term in vitro test for tumour sensitivity to adriamycin based on flow cytometric DNA analysis. Br J Cancer (1983) 0.77
Real-time imaging and quantitative analysis of doxorubicin transport in a perfusable microvessel platform. Integr Biol (Camb) (2016) 0.75
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol (2002) 1.49
Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet (1996) 1.47
Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res (1978) 1.44
Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs (1998) 1.30
Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res (1978) 1.28
In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta (1999) 1.24
Cellular resistance to anthracyclines. Gen Pharmacol (1996) 1.19
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol (1998) 1.15
Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta (1997) 1.15
Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol (2001) 1.11
Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Ann Oncol (2002) 1.09
Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta (1997) 1.08
A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer (2003) 1.08
Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil. Br J Cancer (1987) 1.03
P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Biochim Biophys Acta (1992) 1.02
Membrane transport of anthracyclines. Pharmacol Ther (1982) 1.00
Increase in nonspecific adsorptive endocytosis in anthracycline- and vinca alkaloid-resistant Ehrlich ascites tumor cell lines. J Natl Cancer Inst (1987) 1.00
Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem Pharmacol (1978) 0.98
Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemother Pharmacol (2000) 0.95
Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem (1996) 0.93
Mechanism of resistance to anthracyclines and vinca alkaloids. Prog Clin Biol Res (1983) 0.93
Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor. Cancer Res (1980) 0.89
Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo. A new treatment principle. Cancer Treat Rev (1984) 0.89
Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells. Cancer Chemother Pharmacol (1987) 0.88
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol (2002) 0.87
ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines. Biochim Biophys Acta (1997) 0.86
Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem (1993) 0.82
A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Ann Oncol (1993) 0.82
In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). Br J Cancer (1989) 0.82
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells. Br J Cancer (1990) 0.81
Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells. Biochem Pharmacol (1989) 0.81
Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators. Br J Cancer (1989) 0.80
Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone. Biochem Pharmacol (2000) 0.79
Phase II studies of 4'-iodo-4'-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers. Ann Oncol (1992) 0.79
Carbohydrate antigen 549 in metastatic breast cancer during cytostatic treatment and follow-up. Eur J Cancer (1992) 0.79
Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation. Cancer Chemother Pharmacol (1990) 0.79
The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells. Biochem Pharmacol (1988) 0.79
pH regulation in sensitive and multidrug resistant Ehrlich ascites tumor cells. Cell Physiol Biochem (1998) 0.79
Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo. Cancer Chemother Rep (1975) 0.79
Anthracycline resistance. Acta Oncol (1989) 0.78
In vitro and in vivo study of cross resistance between daunorubicin and daunorubicin-DNA complex in Ehrlich ascites tumor. Cancer Chemother Pharmacol (1979) 0.78
Interaction among two subpopulations of Ehrlich ascites tumor in vivo: evidence of a contact mediated immune response. Acta Pathol Microbiol Immunol Scand A (1987) 0.78
Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation. Int J Radiat Oncol Biol Phys (2001) 0.78
Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil. Biochem Pharmacol (1995) 0.78
Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin. Eur J Haematol Suppl (1987) 0.77
Intermittent high-dose aclarubicin in patients with advanced cancer: a phase I study with special reference to cardiac toxicity. Cancer Treat Rep (1983) 0.77
Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide. Biochem Pharmacol (2000) 0.77
Phase II trial with Brequinar (DUP-785, NSC 368390) in patients with metastatic colorectal cancer: a study of the Early Clinical Trials Group of the EORTC. Ann Oncol (1990) 0.77
P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin. Br J Cancer (1998) 0.77
In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues. Biochem Pharmacol (1990) 0.77
The liver in Hodgkin's disease--II. Histopathologic findings. Eur J Cancer Clin Oncol (1982) 0.77
Cross resistance and cellular uptake of 4'-O-methyldoxorubicin in experimental tumors with acquired resistance to doxorubicin. Cancer Chemother Pharmacol (1981) 0.76
Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study. Ann Oncol (1990) 0.75
Freeze-fracture study of plasma membranes in wild type and daunorubicin-resistant Ehrlich ascites tumor and P388 leukemia cells. Virchows Arch B Cell Pathol Incl Mol Pathol (1989) 0.75
Treatment of small cell lung cancer with 6-mercaptopurine: a phase II study. Cancer Treat Rep (1985) 0.75
Challenging drug resistance in cancer therapy--review of the First Nordic Conference on Chemoresistance in Cancer Treatment, October 9th and 10th, 1997. Acta Oncol (1998) 0.75
Carcino-embryonic antigen in monitoring the growth of human colon adenocarcinoma tumour cells SK-CO-1 and HT-29 in vitro and in nude mice. Eur J Cancer (1997) 0.75
Increased uptake of actinomycin D in Ehrlich ascites tumour cells induced by daunorubicin. Cancer Chemother Pharmacol (1983) 0.75
Adriamycin, an antitumour antibiotic: a review with special reference to daunomycin. Dan Med Bull (1975) 0.75
Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein. Biochem Pharmacol (1994) 0.75
Clinical trial of rubidazone in solid tumors and malignant lymphomas. Cancer Treat Rep (1978) 0.75
Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hematologic toxicity induced by high-dose chemotherapy in patients with metastatic breast cancer. Acta Oncol (1995) 0.75
The liver in Hodgkin's disease--I. Clinico-pathological relations. Eur J Cancer Clin Oncol (1982) 0.75
Multidrug resistance: drug extrusion and its counteraction by chemosensitizers. Eur J Haematol Suppl (1988) 0.75
Phase II study of second-line treatment with high-dose cyclophosphamide in recurrent metastatic breast cancer. Cancer Chemother Pharmacol (1996) 0.75
Cytosolic free Ca2+ in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca2+ changes. Biochem Pharmacol (1991) 0.75
Proopiomelanocortin producing cells of spleen: increase after transplantation with opioid-peptide producing Ehrlich ascites tumor cells. Eur J Cell Biol (1988) 0.75
Lectin staining patterns of plasma membranes of daunorubicin and vincristine resistant Ehrlich ascites tumour cells. Virchows Arch B Cell Pathol Incl Mol Pathol (1988) 0.75